Regardless of breast cancer subtypes, MYC amplification has been reported to be a predictive factor of complete pathologic response to neoadjuvant chemotherapy (Anthracycline-Cyclophosphamide followed by Taxane Docetaxel; AC + T) regimen [45]. The gene discussed is MYC; the disease is breast cancer.